AUTHOR=Huang Linyu , Zhang Xingling , Zhang Jie , Li Long , Zhou Xianyu , Yang Tingyu , An Xuemei 

TITLE=Efficacy of non-invasive brain stimulation for post-stroke sleep disorders: a systematic review and meta-analysis

JOURNAL=Frontiers in Neurology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1420363

DOI=10.3389/fneur.2024.1420363

ISSN=1664-2295

ABSTRACT=<sec id="sec1"><title>Objective</title><p>This study aimed to systematically assess the clinical efficacy of non-invasive brain stimulation (NIBS) for treating post-stroke sleep disorders (PSSD).</p></sec><sec id="sec2"><title>Methods</title><p>We conducted thorough literature search across multiple databases, including PubMed, Web of Science, EmBase, Cochrane Library, Scopus, China Biology Medicine (CBM); China National Knowledge Infrastructure (CNKI); Technology Periodical Database (VIP), and Wanfang Database, focusing on RCTs examining NIBS for PSSD. Meta-analyses were performed using RevMan 5.4 and Stata 14.</p></sec><sec id="sec3"><title>Results</title><p>Eighteen articles were reviewed, including 16 on repetitive Transcranial Magnetic Stimulation (rTMS), one on Theta Burst Stimulation (TBS), and two on transcranial Direct Current Stimulation (tDCS). Meta-analysis results indicated that rTMS within NIBS significantly improved the Pittsburgh Sleep Quality Index (PSQI) score (MD = −1.85, 95% CI [−2.99, −0.71], <italic>p</italic> &lt; 0.05), the 17-item Hamilton Depression Rating Scale (HAMD-17) score [MD = −2.85, 95% CI (−3.40, −2.30), <italic>p</italic> &lt; 0.05], and serum brain-derived neurotrophic factor (BDNF) levels [MD = 4.19, 95% CI (2.70, 5.69), <italic>p</italic> &lt; 0.05], while reducing the incidence of adverse reactions [RR = 0.36, 95% CI (0.23, 0.55), <italic>p</italic> &lt; 0.05]. TBS significantly improved the PSQI score in patients with PSSD (<italic>p</italic> &lt; 0.05). Conversely, tDCS significantly improved the HAMD-17 score in PSSD patients [MD = −1.52, 95% CI (−3.41, −0.64), <italic>p</italic> &lt; 0.05]. Additionally, rTMS improved sleep parameters, including Stage 2 sleep (S2%) and combined Stage 3 and 4 sleep (S3 + S4%) (<italic>p</italic> &lt; 0.05), while tDCS improved total sleep time (TST) and sleep efficiency (SE) (<italic>p</italic> &lt; 0.05).Subgroup analysis results indicated: (1) Both LF-rTMS and HF-rTMS improved PSQI scores (<italic>p</italic> &lt; 0.05). (2) Both rTMS combined with medication and rTMS alone improved PSQI scores (<italic>p</italic> &lt; 0.05). Compared to the sham/blank group, the rTMS group showed improvements in SE, sleep latency (SL), S1%, S3 + S4%, and REM sleep (REM%). The rTMS combined with medication group showed improved SL compared to the medication-only group (<italic>p</italic> &lt; 0.05).</p></sec><sec id="sec4"><title>Conclusion</title><p>NIBS effectively improves sleep quality, structure, depression levels, and BDNF levels in PSSD patients, while also being safe. Further investigations into the potential of NIBS in PSSD treatment may provide valuable insights for clinical applications.</p></sec><sec id="sec5"><title>Systematic review registration</title><p><ext-link xlink:href="https://www.crd.york.ac.uk/prospero/" ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.crd.york.ac.uk/prospero/</ext-link>, CRD42023485317.</p></sec>